Our lab investigates the biology of colorectal cancer and other GI malignancies. We study mechanisms of action and resistance in order to develop rational combinations and novel therapies. One of our primary aims is to facilitate the conduct of early phase clinical trials with a focus on validation of key preclinical mechanisms. We utilize a variety of techniques and models, including 2-D tissue culture, patient-derived organoids, xenografts, and high-throughput analysis of patient specimens. We welcome trainees and potential collaborators to discuss ideas further.
Current topics of interest include:
- inhibition of anti-apoptosis proteins for the treatment of colorectal cancer
- bromodomain and extra-terminal domain (BET) inhibitors in the treatment of colorectal and other cancers
- immune priming of MSS colorectal cancer and other "immune-cold" tumors